Swedish Orphan Biovitrum AB - Long-term Safety and Efficacy Data of Extended Half-life Therapy Alprolix in Children With Haemophilia B Published in The Lancet Haematology Feb 2, 2017 07:46AM
Biogen (BIIB) Completes Separation of Bioverativ (BIVV) Feb 1, 2017 07:33AM
Bioverativ Launches as Global Biotechnology Company Dedicated to Meaningful Progress in Hemophilia Feb 1, 2017 07:30AM
Sobi and Bioverativ to Reveal new Long-term Safety and Efficacy Data of Elocta® and Alprolix® at EAHAD Feb 1, 2017 03:09AM
Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock Jan 12, 2017 08:00AM